#1 Clinical Trials Search in Europe
EU – Europe
AT – Austria
HR – Croatia
CZ – Czech Republic
DK – Denmark
EE – Estonia
FI – Finland
FR – France
DE – Germany
IS – Iceland
IT – Italy
LV – Latvia
LT – Lithuania
NL – Netherlands
NO – Norway
PL – Poland
PT – Portugal
RO – Romania
SK – Slovakia
SI – Slovenia
ES – Spain
SE – Sweden
  • Find a Clinical Trial

    Search Trials by Disease

    Non-small cell lung cancer Breast cancer Plasma cell myeloma Neoplasm Neoplasm malignant Acute myeloid leukaemia Colitis ulcerative Obesity Colorectal cancer metastatic Prostate cancer Crohn's disease Colorectal cancer Dementia Alzheimer's type Ovarian cancer Hepatocellular carcinoma Breast cancer metastatic Dermatitis atopic Asthma Non-small cell lung cancer metastatic Malignant melanoma More trials…
  • Rare Diseases Treatments

    Search Trials by Disease

    Congenital cystic kidney disease Non-small cell lung cancer Epileptic encephalopathy Ehlers-Danlos syndrome Liposarcoma metastatic Thalassaemia Cognitive disorder Infantile apnoea Haematological malignancy Myelodysplastic syndrome Congenital disorder of glycosylation Uveitis Medulloblastoma Craniocerebral injury Crigler-Najjar syndrome More trials…

    Learn about Rare Diseases

    Combined immunodeficiency Biotinidase deficiency – Treatment VEXAS syndrome – Life with Disease Myelodysplastic syndrome with excess blasts – Basic Information Familial amyotrophic lateral sclerosis – Diagnostics Phenylketonuria – Treatment Adrenocortical carcinoma – Diagnostics Toxic epidermal necrolysis – Life with Disease Mucopolysaccharidosis – Diagnostics Acute respiratory distress syndrome More diseases
  • Vaccine Clinical Trials
  • Pediatric Clinical Trials
  • Resources for Patients

    Browse Innovative Treatments

    Tetrahydrouridine Triptorelin Pamoate Emtricitabine Omp12 Doxazosin Bendamustine WEF-001 Anhydrous Cidofovir Haloperidol Sorafenib Nvl-655 MAGNESIUM CARBONATE HEAVY Contezolid Pemetrexed Disodium Rbl012.2 Fenofibrate ANOC-001 LVT-001 Hepatitis B Surface Antigen Dermatophagoides Farinae More therapies…

    Learn about Your Condition

    Follicular lymphoma stage IV Albuminuria Short-bowel syndrome Hyperchylomicronaemia Chondrocalcinosis Pneumococcal infection Neuroendocrine tumour Pustular psoriasis CDKL5 deficiency disorder Bacterial infection Mitochondrial myopathy Double hit lymphoma Paedophilia Anaemia Graft versus host disease More diseases
  • Healthy Volunteers
  • Patient Guide
  • Our Partners
  • About Us
  • Contact us
  • Region
    🇪🇺 Europe
    🇦🇹 Austria
    🇭🇷 Croatia
    🇨🇿 Czech Republic
    🇩🇰 Denmark
    🇪🇪 Estonia
    🇫🇮 Finland
    🇫🇷 France
    🇩🇪 Germany
    🇮🇸 Iceland
    🇮🇹 Italy
    🇱🇻 Latvia
    🇱🇹 Lithuania
    🇳🇱 Netherlands
    🇳🇴 Norway
    🇵🇱 Poland
    🇵🇹 Portugal
    🇷🇴 Romania
    🇸🇰 Slovakia
    🇸🇮 Slovenia
    🇪🇸 Spain
    🇸🇪 Sweden

Plasma cell myeloma refractory

  • Study of teclistamab plus autologous lymphocyte infusion in patients with relapsed or refractory multiple myeloma

    Not yet recruiting

    2 1 1 1
    Investigated Drugs:
    • Teclistamab
    Italy

  • A study of mezigdomide, carfilzomib, and dexamethasone in patients with relapsed or refractory multiple myeloma.

    Not yet recruiting

    2 1 1 1
    Investigated Diseases:
    • Plasma cell myeloma refractory
    Investigated Drugs:
    • Mezigdomide
    • Carfilzomib
    • Dexamethasone
    France

  • A Study of Linvoseltamab Alone and Linvoseltamab with Carfilzomib Compared to Standard Treatment in Adults with Relapsed or Refractory Multiple Myeloma

    Not yet recruiting

    3 1 1 1
    Investigated Diseases:
    • Plasma cell myeloma refractory
    Investigated Drugs:
    • Aciclovir
    • Diphenhydramine Hydrochloride
    • Dexamethasone Phosphate
    Austria Belgium Czechia France Germany Greece +4

  • Study on Melflufen and Dexamethasone for Elderly Patients with Relapsed Multiple Myeloma

    Not yet recruiting

    2 1 1 1
    Investigated Diseases:
    • Plasma cell myeloma refractory
    • Plasma cell myeloma
    Investigated Drugs:
    • Melphalan Flufenamide
    • Dexamethasone Sodium Phosphate
    Italy

  • A Phase 2 Study of JNJ-79635322 in Patients with Relapsed or Refractory Multiple Myeloma

    Not recruiting

    2 1 1
    Investigated Drugs:
    • IGG1 TRISPECIFIC MONOCLONAL ANTIBODY AGAINST T-CELL RECEPTOR CD3, B-CELL MATURATION ANTIGEN AND G PROTEIN-COUPLED RECEPTOR CLASS C GROUP 5 MEMBER D
    Italy Poland

  • Study Comparing Anitocabtagene Autoleucel with Standard Treatment for Patients with Relapsed or Refractory Multiple Myeloma

    Not recruiting

    3 1 1 1
    Investigated Drugs:
    • Anitocabtagene Autoleucel
    • Bortezomib
    • Carfilzomib
    Austria Belgium Czechia France Germany Italy +3
Previous Page
1 2 3 4 5 6 7
Next Page

Investigational Drugs in This Location

See which drug candidates are part of clinical trials near you. Click for detailed trial information.

Medical Conditions Being Studied in This Location

Explore diseases currently included in clinical trials near you. Click to view trials and details for each condition.

European Clinical Trials Information Network

The European Clinical Trials Information Network is transforming access to clinical trial information for patients across Europe. By overcoming language barriers, our platform allows everyone, regardless of their native language, to easily find relevant and comprehensible clinical trial data. This innovative service connects patients to cutting-edge treatments, creating a unified European community where health and progress transcend borders.

This service is not affiliated with the European Commission, the EMA, or the official CTIS system. Most information comes from publicly available international clinical-trial registries, supplemented by data from academic centres, national regulators, and commercial sponsors. We aim to keep all content accurate and up to date.

Explore the full ecosystem of clinical research in Europe.

The information provided on this website is mainly derived from international public clinical trial databases (CTIS.eu). In addition, we are including supplementary sources, such as information provided by academic centers and national regulators, as well as information supplied by commercial sponsors (pharmaceutical companies and contract research organizations). We try to ensure that the information provided is accurate and up to date.

Certain content and visual elements on this website have been generated or enhanced using artificial intelligence (AI).

The website is published by:
CTIN POLAND sp. z o.o.
with its registered office in Warsaw,
ul. rtm. Witolda Pileckiego 67/109,
02-781 Warsaw, Poland,
entered in the Register of Entrepreneurs of the National Court Register under KRS number 0001111334,
REGON: 528919042, NIP (Tax ID): 9512598637
Contact us

© 2026 CTIN Poland

Privacy Policy

Terms and Conditions

Contact

For Sites and Sponsors

Clinical Trial Locations

We use cookies

The website uses cookies to ensure the proper functioning of the site and to analyze internet traffic. Some cookies are essential for using the service and do not require consent. You can accept all cookies or use only the essential ones. Data is processed in accordance with our Privacy Policy. You have the right to withdraw your consent, access, rectify, delete, or limit the processing of your data at any time.
Numer nieprawidłowy!
Numer nieprawidłowy!